<DOC>
	<DOCNO>NCT02569515</DOCNO>
	<brief_summary>This study evaluate tolerability , effect quality life , patient receive multi-dose NeoRecormon administer RecoPen predialysis patient chronic renal anemia . The anticipated time study treatment 10 month , target sample size 60 individual .</brief_summary>
	<brief_title>A Study Epoetin Beta ( NeoRecormon ) Predialysis Patients With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patient 1865 year age Chronic renal failure ( Stages IIII ) No previous epoetin therapy Poorly control hypertension History evidence malignancy Relevant acute chronic bleeding ( require therapy ) within 3 month study drug Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>